<DOC>
	<DOCNO>NCT02606682</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability blood level orally administer NPT200-11 healthy subject . In addition , maximally tolerate dose determine .</brief_summary>
	<brief_title>Phase 1 Study NPT200-11 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Subjects meet follow inclusion criterion eligible participate study : 1. informed , willing able comply , protocol requirement investigational nature study , sign informed consent form accordance institutional regulatory guideline ; 2. male female adult 18 55 year age , inclusive ; 3. female subject must postmenopausal least 2 year surgically sterile ( hysterectomy , bilateral oophorectomy , tubal ligation ) ; 4. male subject must willing use adequate barrier method contraception duration study 90 day dose sperm donation duration study 90 day dose . Male subject surgically sterile need employ method contraception ; 5. nonsmoker least six month ; 6 . BMI = 18 30 kg/m2 , inclusive ; 7. good health , judgment Principal Investigator , determine : medical history indicative serious severe chronic condition require frequent medical intervention continual pharmacologic management , medical social condition would potentially interfere subject 's ability comply study visit schedule study assessment ; clinically significant abnormality body temperature , heart rate , respiratory rate , blood pressure ; clinically significant abnormality 12lead electrocardiogram ( ECG ) ; clinically significant abnormality clinical chemistry ( ALT , AST , total bilirubin must upper limit normal eGFR must 90 mL/min ) , hematology ( hemoglobin ≥ 12.0 g/dL ) , coagulation urinalysis ; lab test may repeat , necessary ( detail provide attached flow chart study assessment ) . 8. negative result follow screen laboratory test : urine drug screen , urine alcohol screen , serum pregnancy test , hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus antibody . Subjects meet follow exclusion criterion NOT eligible participate study : female child bear potential ; history significant medical condition may interfere absorption , distribution elimination NPT20011 , clinical laboratory safety assessment study ; history drug hypersensitivity disorder affect respiratory function ( e.g. , COPD , asthma ) cardiac disorder predispose cardiac adverse event ; history current alcohol abuse and/or drug addiction &lt; 2 year prior screen , positive urine drug alcohol screen ( e.g. , amphetamine , barbiturate , benzodiazepine , opiate , cannabinoids , alcohol cocaine ) ; positive HBVsAg , HCV Ab , HIV Ab ; 12 lead ECG show follow : correct QTc interval &gt; 450 msec &lt; 320 msec ( Fridericia 's correction ) ; sustain sit systolic blood pressure &gt; 140 &lt; 90 mm Hg sit diastolic blood pressure &gt; 90 &lt; 50 mm Hg Screening Day 1 ( sentinel pair ) Day 1 ( remain 6 subject cohort ) , average 2 assessment BP take visit use exclude subject ; rest pulse rate screen &gt; 100 &lt; 45 ; donate lose &gt; 500 mL blood &lt; 56 day prior enrollment study ; plasma donation within 7 day prior enrollment study ; active infection febrile illness &lt; 14 day prior first dose study medication ; use prescription overthecounter medication herbal supplement ≤ 14 day prior dose completion followup visit Day 7 ; participate clinical study new chemical entity within 30 day prior admission CRU .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>